Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTI Seeks ASP Payment For Zevalin; Medicare Cap Temporarily Lifted

Executive Summary

After winning a short-term reprieve from Medicare's payment cap on radioimmunotherapies, Cell Therapeutics will focus on convincing CMS to pay for those drugs under Part B's average sales price formula
Advertisement

Related Content

Comparative Effectiveness Bill Calls For Private Group To Plan Research
Comparative Effectiveness Bill Calls For Private Group To Plan Research
CMS Open To ASPs For Radiopharmaceuticals; Congress Blocks Rate Cap
CMS Open To ASPs For Radiopharmaceuticals; Congress Blocks Rate Cap
Radiopharmaceuticals May Be Eligible For ASP Reimbursement Under CMS Proposal
Researchers Detail Favorable Zevalin Data At ASH, But Also Medicare Concern
Researchers Detail Favorable Zevalin Data At ASH, But Also Medicare Concern
Medicare Rates For Hospital Outpatient Drugs Lowered To ASP+5% In 2008
Advertisement
UsernamePublicRestriction

Register

PS049145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel